Safety, tolerability, pharmacokinetics, and efficacy of AZD3759 in EGFR-mutant NSCLC with CNS metastases

El acceso al contenido completo es sólo para profesionales sanitarios registrados. Regístrate para leer más

Background

CNS metastases—including brain and leptomeningeal metastases—from epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) are associated with poor prognosis. AZD3759 is a novel EGFR tyrosine kinase inhibitor with high capability to penetrate the blood...